Biological Variation of Erythrocyte Total, Metal-Free, and Zinc Protoporphyrin IX in Patients with Erythropoietic Protoporphyria and Healthy Subjects: Implications for Clinical Interpretation and Monitoring
Clinical Chemistry · 2025
DOI: 10.1093/clinchem/hvaf055 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Chemistry, 2025. Verfasst von Paul Kjetel Soldal Lillemoen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Biochemistry and Pharmacology, Haukeland University Hospital, Bergen, Norway. Hauptthemen laut MEDLINE: Protoporphyrins, Protoporphyria, Erythropoietic, Erythrocytes. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
There is a lack of robust biological variation (BV) data for porphyria-related biomarkers. Our study aimed to estimate BV of erythrocyte total, metal-free, and zinc protoporphyrin IX in patients with erythropoietic protoporphyria (EPP) and healthy subjects and to explore the clinical implications of these data.
Methods
Fourteen patients with EPP and 15 healthy subjects were sampled quarterly for 2 years, and erythrocyte protoporphyrin analyses were performed in duplicate in all samples. A Bayesian method was used to estimate the within-subject (CVI) and personal (CVP(i)) BV.
Results
Based on clinical and laboratory assessments, EPP patients were stable during the study, with only 2 data points excluded. CVI in the EPP cohort was estimated as 9.8% (95% credible interval 8.5%–11.5%) for erythrocyte total protoporphyrin, 10.5% (9.0%–12.3%) for metal-free protoporphyrin, and 5.9% (4.3%–8.0%) for zinc protoporphyrin. Baseline metal-free protoporphyrin ranged from 6.9 to 139.8 µmol/L, but the CVP(i)s derived for each patient were similar (20th and 80th percentile of predicted distribution 9.5%–11.5%), and data were homogeneously distributed. Metal-free protoporphyrin was not measurable in the healthy cohort. Data for zinc protoporphyrin were heterogeneously distributed in both study cohorts.
Conclusions
The EPP patients had different set points for metal-free protoporphyrin, but the CVP(i) was similar, supporting the use of the same treatment goals when monitoring. This study is the first to use Bayesian analysis to demonstrate that personal BV is similar in patients with stable, chronic disease and different set points.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medical Biochemistry and Pharmacology, Haukeland University Hospital, Bergen, Norway.
- Norwegian Organization for Quality Improvement of Laboratory Examinations (Noklus), Haraldsplass Deaconess Hospital, Bergen, Norway.
- Norwegian Porphyria Centre, Haukeland University Hospital, Bergen, Norway.
- Department of Global Health and Primary Care, Faculty of Medicine, University of Bergen, Bergen, Norway.
ORCID-Profile: Aasne Karine Aarsand
Zitieren
APA
Lillemoen, P. K. S., Fauskanger, P. K., Sandberg, S., & Aarsand, A. K. (2025). Biological Variation of Erythrocyte Total, Metal-Free, and Zinc Protoporphyrin IX in Patients with Erythropoietic Protoporphyria and Healthy Subjects: Implications for Clinical Interpretation and Monitoring. Clinical Chemistry. https://doi.org/10.1093/clinchem/hvaf055
Vancouver
Lillemoen PKS, Fauskanger PK, Sandberg S, Aarsand AK. Biological Variation of Erythrocyte Total, Metal-Free, and Zinc Protoporphyrin IX in Patients with Erythropoietic Protoporphyria and Healthy Subjects: Implications for Clinical Interpretation and Monitoring. Clinical Chemistry. 2025. doi:10.1093/clinchem/hvaf055
BibTeX
@article{Lillemoen2025,
author = {Lillemoen, Paul Kjetel Soldal and Fauskanger, Pernille Kjeilen and Sandberg, Sverre and Aarsand, Aasne Karine},
title = {Biological Variation of Erythrocyte Total, Metal-Free, and Zinc Protoporphyrin IX in Patients with Erythropoietic Protoporphyria and Healthy Subjects: Implications for Clinical Interpretation and Monitoring},
journal = {Clinical Chemistry},
year = {2025},
doi = {10.1093/clinchem/hvaf055}
}
EUVIMED